The relationship between radiation dose and bevacizumab-related imaging abnormality in patients with brain tumors: A voxel-wise normal tissue complication probability (NTCP) analysis

Purpose Bevacizumab-related imaging abnormality (BRIA), appearing as areas of restricted diffusion on magnetic resonance imaging (MRI) and representing atypical coagulative necrosis pathologically, has been observed in patients with brain tumors receiving radiotherapy and bevacizumab. We investigated the role of cumulative radiation dose in BRIA development in a voxel-wise analysis. Methods Patients (n = 18) with BRIA were identified. All had high-grade gliomas or brain metastases treated with radiotherapy and bevacizumab. Areas of BRIA were segmented semi-automatically on diffusion-weighted MRI with apparent diffusion coefficient (ADC) images. To avoid confounding by possible tumor, hypoperfusion was confirmed with perfusion imaging. ADC images and radiation dose maps were co-registered to a high-resolution T1-weighted MRI and registration accuracy was verified. Voxel-wise normal tissue complication probability analyses were performed using a logistic model analyzing the relationship between cumulative voxel equivalent total dose in 2 Gy fractions (EQD2) and BRIA development at each voxel. Confidence intervals for regression model predictions were estimated with bootstrapping. Results Among 18 patients, 39 brain tumors were treated. Patients received a median of 4.5 cycles of bevacizumab and 1–4 radiation courses prior to BRIA appearance. Most (64%) treated tumors overlapped with areas of BRIA. The median proportion of each BRIA region of interest volume overlapping with tumor was 98%. We found a dose-dependent association between cumulative voxel EQD2 and the relative probability of BRIA (β0 = -5.1, β1 = 0.03 Gy-1, γ = 1.3). Conclusions BRIA is likely a radiation dose-dependent phenomenon in patients with brain tumors receiving bevacizumab and radiotherapy. The combination of radiation effects and tumor microenvironmental factors in potentiating BRIA in this population should be further investigated.

[1]  R. Mohan,et al.  Radiation-Induced Esophagitis in Non-Small-Cell Lung Cancer Patients: Voxel-Based Analysis and NTCP Modeling , 2022, Cancers.

[2]  D. Jäger,et al.  Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases , 2020, Neuro-oncology advances.

[3]  M. J. van den Bent,et al.  Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. , 2018, The Lancet Oncology.

[4]  David A Jaffray,et al.  Voxel-by-voxel correlation between radiologically radiation induced lung injury and dose after image-guided, intensity modulated radiotherapy for lung tumors. , 2017, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

[5]  K. Brock,et al.  Use of image registration and fusion algorithms and techniques in radiotherapy: Report of the AAPM Radiation Therapy Committee Task Group No. 132 , 2017, Medical physics.

[6]  A. Dale,et al.  Regional susceptibility to dose-dependent white matter damage after brain radiotherapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  A. Dale,et al.  Cerebral Cortex Regions Selectively Vulnerable to Radiation Dose-Dependent Atrophy. , 2017, International journal of radiation oncology, biology, physics.

[8]  P. LaViolette,et al.  Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma , 2016, American Journal of Neuroradiology.

[9]  M. Rosenblum,et al.  Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients. , 2016, Neuro-oncology.

[10]  N. Nonoguchi,et al.  Delayed brain radiation necrosis: pathological review and new molecular targets for treatment , 2015, Medical Molecular Morphology.

[11]  J. Hesselink,et al.  Bevacizumab: radiation combination produces restricted diffusion on brain MRI. , 2014, CNS oncology.

[12]  A. Dale,et al.  Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria) , 2014, Journal of Neuro-Oncology.

[13]  E. Hattingen,et al.  Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma , 2014, Neurology.

[14]  J. Raizer,et al.  Diffusion abnormalities of the corpus callosum in patients receiving bevacizumab for malignant brain tumors: suspected treatment toxicity , 2014, Journal of Neuro-Oncology.

[15]  A. Dale,et al.  Restriction-Spectrum Imaging of Bevacizumab-Related Necrosis in a Patient with GBM , 2013, Front. Oncol..

[16]  T. Cloughesy,et al.  Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas Are Associated with Improved Survival Compared with Matched Controls , 2012, American Journal of Neuroradiology.

[17]  L. Hlatky,et al.  Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in their Antitumor Profiles , 2011, Dose-response : a publication of International Hormesis Society.

[18]  W. Curry,et al.  Exacerbation of cerebral radiation necrosis by bevacizumab. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[20]  Tracy T Batchelor,et al.  Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. , 2010, Neuro-oncology.

[21]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Frosch,et al.  Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Harris,et al.  Phase I/II Trial of Bevacizumab and Radiotherapy for Locally Advanced Inoperable Colorectal Cancer: Vasculature-Independent Radiosensitizing Effect of Bevacizumab , 2009, Clinical Cancer Research.

[24]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Y. Yoshii.  Pathological review of late cerebral radionecrosis , 2008, Brain Tumor Pathology.

[26]  P. Sminia,et al.  Reirradiation tolerance of the human brain. , 2008, International journal of radiation oncology, biology, physics.

[27]  Thomas L Chenevert,et al.  Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. , 2006, Magnetic resonance imaging.

[28]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[29]  Peter Vaupel,et al.  Tumor microenvironmental physiology and its implications for radiation oncology. , 2004, Seminars in radiation oncology.

[30]  A. Dicker,et al.  Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  A. Marmarou,et al.  Biomechanics of brain edema and effects on local cerebral blood flow. , 1980, Advances in neurology.